Annemieke J. Willemze
Amsterdam, NH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Individual Comparative PK Evaluation of Single-dose Octocog Alfa, Rurioctocog Alfa Pegol, and Efanesoctocog Alfa in Adults with Severe Hemophilia A.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: March 31, 2026
Treatment satisfaction and patient preference for efanesoctocog alfa over previous hemophilia A treatment: Results from the XTEND-1 phase 3 clinical trial.
Journal: Current therapeutic research, clinical and experimental
Published: March 19, 2026
A Psychometric Analysis of the Haemophilia Quality of Life Questionnaire for Adults Physical Health Subscale and Total Scores: Data From the Phase 3 XTEND-1 Trial in Patients With Severe Haemophilia A.
Journal: Haemophilia : the official journal of the World Federation of Hemophilia
Published: November 05, 2025
Unilateral Versus Bilateral Ultrasound of the Hands in Patients With Clinically Suspect Arthralgia: What Is the Difference? A Longitudinal Study.
Journal: The Journal of rheumatology
Published: October 23, 2025
Corrigendum: Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: August 27, 2025
Effectiveness and cost-effectiveness of a multimodal, physiotherapist-led, vocational intervention for people with rheumatoid arthritis or axial spondyloarthritis and a reduced work ability: a randomized, controlled trial.
Journal: Rheumatology international
Published: July 31, 2025
Outcomes in participants switching from FVIII replacement therapy to efanesoctocog alfa prophylaxis in XTEND-1: a post hoc analysis.
Journal: Therapeutic advances in hematology
Published: May 21, 2025
A phase 1, open-label study to assess the pharmacokinetics, safety, and tolerability of a single intravenous injection of efanesoctocog alfa in adults with type 2N or type 3 von Willebrand disease.
Journal: Journal of thrombosis and haemostasis : JTH
Published: February 26, 2025
Efanesoctocog Alfa Population Pharmacokinetics and Repeated Time-To-Event Analysis of Bleeds in Adults, Adolescents, and Children with Severe Hemophilia A.
Journal: Journal of clinical pharmacology
Published: November 19, 2024
Prospective, Observational Study of the Clinical Outcomes of FVIII Treatment in Adults and Adolescents with Severe Haemophilia A.
Journal: TH open : companion journal to thrombosis and haemostasis
Published: October 29, 2024
Treatment of Bleeding Episodes With Efanesoctocog Alfa in Previously Treated Patients With Severe Hemophilia A in the Phase 3 XTEND-1 Study.
Journal: American journal of hematology
Published: August 06, 2024
Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews.
Journal: Clinical therapeutics
Published: April 08, 2024
Last Updated: 09/26/2026